This study explores the role of methoxy polyethylene glycol@Elabela-11 (mPEG@ELA-11), a pH-responsive ELA-11 conjugate, in modulating macrophage function and attenuating atherosclerosis, focusing on the protein kinase B (AKT)-mediated endoplasmic reticulum (ER) stress pathway as a molecular target. 

CSHL postdoc Miguel Santo Domingo Martinez and colleagues in the Lippman lab have used CRISPR gene editing to produce more compact goldenberry crops, making them easier to grow and harvest. The development could help bring this tasty fruit to farms and grocery stores around the globe.

Universidad Carlos III de Madrid (UC3M), in collaboration with the National Cybersecurity Institute (INCIBE), an entity under the Ministry for Digital Transformation and Public Administration through the Secretariat of State for Telecommunications and Digital Infrastructure, have promoted the development of a new probabilistic metric designed to more accurately measure the level of privacy and protection that users have in different databases.

Hypertrophic chondrocytes are deeply involved in the growth of mammalian bones. Researchers find that these cells transform into multiple functional cell types, including those responsible for lengthening bones, maintaining the periosteum, and promoting the invasion of blood vessels that supply newly formed bone. Thrombospondin-4, a key signaling molecule produced by these cells, drives blood vessel formation. These findings open new avenues for enhancing bone repair and healing injured bones.

Lithium is a strategically very important mineral in the present decade. Latin American countries, with their abundant resources, have taken divergent paths in terms of governance strategies. In a recent study, a researcher from Jeonbuk National University has proposed a two-stage decision-making framework to explain this trend, providing a useful starting point for examining how states navigate the interplay between external pressures and domestic structural constraints in governing lithium industries.

A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country’s racial and ethnic makeup, with an increasing trend of trials underrepresenting Black and Hispanic individuals.